Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Microsoft Taps AWS to Support GitHub Amid AI Coding Boom 
Trump Says Anthropic No Longer Seen as National Security Threat 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
Chinese Social Media Giant Xiaohongshu Eyes Hong Kong IPO at Over $70 Billion Valuation 
Qantas Nears Launch of World’s Longest Non-Stop Flights to London and New York 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
BHP Shares Fall as Jansen Potash Project Costs Surge 
Trump Administration Delays DeepSeek and CXMT Trade Blacklist Designations Amid U.S.-China Tensions 
SpaceX Surpasses Amazon in Market Value as Post-IPO Rally Accelerates 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
India’s Sun Pharmaceutical Industries (NSE: SUN) has announced a major acquisition, agreeing to purchase U.S.-based Organon & Co (NYSE: OGN) in an all-cash deal valued at approximately $11.75 billion. The move marks a significant step in Sun Pharma’s strategy to expand its global presence and strengthen its position in key pharmaceutical segments, including women’s health, branded generics, innovative medicines, and biosimilars.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash. This acquisition is expected to significantly enhance Sun Pharma’s product portfolio by adding more than 70 established and innovative medicines across women’s health and general therapeutic areas. Organon’s strong footprint in over 140 international markets will also provide Sun Pharma with broader geographic reach and improved market penetration.
Organon, which was spun off from Merck (NYSE: MRK) in 2021, has demonstrated solid financial performance. The company reported revenue of $6.2 billion and adjusted EBITDA of $1.9 billion for 2025, making it an attractive target for expansion-focused pharmaceutical companies. By integrating Organon’s assets, Sun Pharma aims to accelerate growth and diversify its revenue streams.
Following the completion of the deal, the combined entity is projected to generate pro forma revenue of around $12.4 billion. This would position Sun Pharma among the top 25 global pharmaceutical companies. Additionally, the acquisition is expected to establish Sun Pharma as a top-three player in the global women’s health market and the seventh-largest company in the biosimilars segment.
Sun Pharma plans to finance the transaction through a combination of internal cash reserves and committed bank financing. The deal has already received approval from both companies’ boards and is expected to close in early 2027, pending regulatory clearances and shareholder approvals. This strategic acquisition underscores Sun Pharma’s ambition to become a leading global pharmaceutical powerhouse while expanding its influence in high-growth therapeutic areas.
